Showing results (361-370 of 422) with videos related to
Sort By:
Pageof 43
Hemasphere|February 20, 2020
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network StudyLucia Morello, Sara Rattotti, Laura Giordano, et al.Hematological Oncology|July 21, 2019
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD NetworkIrene Della Starza, Marzia Cavalli, Lucia Anna De Novi, et al.Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.Journal of Minimally Invasive Gynecology|February 14, 2015
How to Manage Bowel Endometriosis: The ETIC ApproachGiulia Alabiso, Luigi Alio, Saverio Arena, et al.Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.Haematologica|December 31, 2011
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Daniela Capello, Mirija Svaldi, et al.American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.Pageof 43